In this study, we performed a systematic review and meta-analyses of the therapeutic effects and adverse events of both AI and CDK4/6 inhibitor combination therapy and fulvestrant 500 mg monotherapy compared to AI monotherapy as the optimal first-line endocrine therapy for postmenopausal women with HR-positive HER2-negative breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.